20939 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Integrin superfamily
IDENTIFICATION OF HIGHLY IMMUNOSUPRESIVE TREG POPULATION IN TUMOR MICROENVIRONMENTS
#2VEGFR FUSION PROTEIN PHARMACEUTICAL COMPOSITION
#3TARGETED THROMBOLYSIS FOR TREATMENT OF MICROVASCULAR THROMBOSIS
#4MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#5FUSED IN SARCOMA (FUS) NUCLEAR TRANSLOCATION INHIBITORS FOR PREVENTING FIBROSIS
#6A PHARMACEUTICALLY ACCEPTABLE AQUEOUS GEL COMPOSITION FOR MRNA DELIVERY
#7MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#8VEGFR fusion protein pharmaceutical composition
#9Compositions and methods for treatment of GCase related disease states
#10MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#11Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
#12PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CARTILAGE DISEASES
#13FUSED IN SARCOMA (FUS) NUCLEAR TRANSLOCATION INHIBITORS FOR PREVENTING FIBROSIS
#14METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY
#15Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
#16COMBINATION TUMOR TREATMENT WITH AN INTEGRIN-BINDING-FC FUSION PROTEIN AND IMMUNE STIMULATOR
#17Targeted Thrombolysis for Treatment of Microvascular Thrombosis
#18Compositions and methods for treatment of GCASE related disease states
#19POLYPEPTIDE NANOTUBES LINKED BY DISULFIDE BONDS FOR TARGETED DELIVERY OF CYTOTOXIC THERAPIES
#20METHOD OF TREATING PEDIATRIC DISORDERS
#21IMMUNOMODULATING CELL CIRCUITS
#22Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
#23MESENCHYMAL STEM CELLS AND PHARMACEUTICAL COMPOSITION
#24Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis
#25Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
#26PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CARTILAGE DISEASES
#27METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS
#28Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
#29Compositions and methods for treatment of Gcase related disease states
#30Method for treatment or prevention of a cancer
#31Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
#32Methods and compositions for wound treatment
#33Compounds and methods of modulating angiogenesis
#34Compositions and methods to improve adoptive cell therapies
#35METHODS FOR DIAGNOSING AND TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
#36CHAPERONE-BASED INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
#37Compounds and methods of modulating angiogenesis
#38Methods and compositions for wound treatment
#39Methods and compositions for wound treatment
#40PROLIFERATION-ASSOCIATED MODULATION OF THE SPLICING OF THE INTEGRIN ALPHA 6 ISOFORMS
#41OIL BODY CARRIERS, USES IN TARGET THERAPY AND/OR DETECTION OF THE SAME, AND FUSION PROTEINS COMPRISED THEREIN
#42Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
#43Method for enhancing or inhibiting insulin-like growth factor-I
#44COMPOUNDS AND METHODS FOR MODULATING INTEGRIN ACTIVITY
#45Vessel enlargement by arteriogenic factor delivery
#46Homing of cells to myocardium
#47Method for the treatment of automimmune diseases comprising administering rapamycin and IL-10
#48PRINTING APPARATUS, PRINTING METHOD, AND PRINT HEAD
#49Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface
#50Rapamycin and il-10 for the treatment of immune diseases
#51Method for enhancing or inhibiting insulin-like growth factor-I
#52Novel immunotherapy
#53Printing apparatus, printing method, and print head
#54TGF-beta activation and use